Clinical benefit of fixed-dose dual bronchodilation with glycopyrronium and indacaterol once daily in patients with chronic obstructive pulmonary disease: a systematic review
International Journal of COPD2014Vol. 9, pp. 331–331
Citations Over TimeTop 10% of 2014 papers
Abstract
Fixed-dose indacaterol/glycopyrronium has clinically relevant effects on important COPD outcome measures and is, in general, superior to therapy with a single long-acting bronchodilator (with or without inhaled corticosteroid) indicating long-acting dual bronchodilation as a potential important maintenance therapeutic option for patients with symptomatic COPD, possibly also for the treatment of naïve patients.
Related Papers
- → Therapeutic potential for novel ultra long-acting β2-agonists in the management of COPD: biological and pharmacological aspects(2011)20 cited
- → ONCE-DAILY INDACATEROL PROVIDES SUPERIOR BRONCHODILATION, HEALTH STATUS AND CLINICAL OUTCOMES COMPARED WITH SALMETEROL IN PATIENTS WITH CHRONIC OBSTRUCTIVE COPD: A 26-WEEK PLACEBO-CONTROLLED STUDY(2009)8 cited
- → Indacaterol provides sustained 24h bronchodilation on once-daily dosing in asthma: a 7-day dose-ranging study(2009)4 cited
- → Indacaterol Once-Daily Provides Sustained 24-h Bronchodilation over 52 Weeks of Treatment in COPD.(2009)3 cited
- → ONCE-DAILY INDACATEROL PROVIDES EFFECTIVE 24-HOUR BRONCHODILATION IN COPD: A DOUBLE-BLIND COMPARISON WITH TIOTROPIUM(2009)5 cited